Amantadine Hydrochloride

Amantadine Hydrochloride

Amantadine Hydrochloride Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Deaths

Deaths have been reported from overdose with amantadine. The lowest reported acute lethal dose was 1 gram. Acute toxicity may be attributable to the anticholinergic effects of amantadine. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension (see OVERDOSAGE).

Suicide Attempts

Suicide attempts, some of which have been fatal, have been reported in patients treated with amantadine, many of whom received short courses for influenza treatment or prophylaxis. The incidence of suicide attempts is not known and the pathophysiologic mechanism is not understood. Suicide attempts and suicidal ideation have been reported in patients with and without prior history of psychiatric illness. Amantadine can exacerbate mental problems in patients with a history of psychiatric disorders or substance abuse. Patients who attempt suicide may exhibit abnormal mental states which include disorientation, confusion, depression, personality changes, agitation, aggressive behavior, hallucinations, paranoia, other psychotic reactions and somnolence or insomnia. Because of the possibility of serious adverse effects, caution should be observed when prescribing amantadine hydrochloride capsules to patients being treated with drugs having CNS effects, or for whom the potential risks outweigh the benefit of treatment.

CNS Effects

Patients with a history of epilepsy or other “seizures” should be observed closely for possible increased seizure activity.

Patients receiving amantadine hydrochloride capsules who note central nervous system effects or blurring of vision should be cautioned against driving or working in situations where alertness and adequate motor coordination are important.

Other

Patients with a history of congestive heart failure or peripheral edema should be followed closely as there are patients who developed congestive heart failure while receiving amantadine hydrochloride capsules.

Patients with Parkinson’s disease improving on amantadine hydrochloride capsules should resume normal activities gradually and cautiously, consistent with other medical considerations, such as the presence of osteoporosis or phlebothrombosis.

Because Amantadine Hydrochloride Capsules, USP has anticholinergic effects and may cause mydriasis, it should not be given to patients with untreated angle closure glaucoma.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Influenza A Prophylaxis

Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response.

Influenza A Treatment

Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients.

There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains.

The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules.

Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.
Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules.
Parkinson’s Disease/Syndrome

Amantadine hydrochloride capsules are indicated in the treatment of idiopathic Parkinson’s disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson’s disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established.

Drug-Induced Extrapyramidal Reactions

Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs.

History

There is currently no drug history available for this drug.

Other Information

Amantadine hydrochloride is designated chemically as 1-adamantanamine hydrochloride. Its molecular weight is 187.71 with a molecular formula C10H18NCl. It has the following structural formula:

amantadine chemical structure

Amantadine hydrochloride is a stable white or nearly white crystalline powder, freely soluble in water and soluble in alcohol and in chloroform.

Amantadine hydrochloride has pharmacological actions as both an anti-Parkinson and an antiviral drug.

Amantadine hydrochloride is available as 100 mg capsules for oral administration. Inactive ingredients: corn starch, croscarmellose sodium, ethylcellulose, FD&C Blue #1, FD&C Red #40, gelatin, magnesium stearate, methylparaben, microcrystalline cellulose, pregelatinized starch, propylparaben, sodium lauryl sulfate and titanium dioxide.

Amantadine Hydrochloride Manufacturers


  • A-s Medication Solutions Llc
    Amantadine Hydrochloride Capsule [A-s Medication Solutions Llc]
  • American Health Packaging
    Amantadine Hydrochloride Capsule [American Health Packaging]
  • Stat Rx Usa Llc
    Amantadine Hydrochloride Capsule [Stat Rx Usa Llc]
  • Remedyrepack Inc.
    Amantadine Hydrochloride Capsule [Remedyrepack Inc. ]
  • Lannett Company, Inc.
    Amantadine Hydrochloride Capsule [Lannett Company, Inc.]
  • Upsher-smith Laboratories, Inc.
    Amantadine Hydrochloride Capsule [Upsher-smith Laboratories, Inc.]
  • Pd-rx Pharmaceuticals, Inc.
    Amantadine Hydrochloride Capsule, Gelatin Coated [Pd-rx Pharmaceuticals, Inc.]
  • Ncs Healthcare Of Ky, Inc Dba Vangard Labs
    Amantadine Hydrochloride Capsule [Ncs Healthcare Of Ky, Inc Dba Vangard Labs]
  • Upsher-smith Laboratories, Inc
    Amantadine Hydrochloride Tablet [Upsher-smith Laboratories, Inc]
  • Mylan Institutional Inc.
    Amantadine Hydrochloride Capsule, Gelatin Coated [Mylan Institutional Inc.]
  • Upsher-smith Laboratories, Inc
    Amantadine Hydrochloride Capsule, Gelatin Coated [Upsher-smith Laboratories, Inc]
  • Lake Erie Medical Dba Quality Care Products Llc
    Amantadine Hydrochloride Capsule [Lake Erie Medical Dba Quality Care Products Llc]
  • Mylan Institutional Inc.
    Amantadine Hydrochloride Capsule [Mylan Institutional Inc.]
  • A-s Medication Solutions Llc
    Amantadine Hydrochloride Capsule [A-s Medication Solutions Llc]
  • Sandoz Inc
    Amantadine Hydrochloride Capsule [Sandoz Inc]
  • Aidarex Pharmaceuticals Llc
    Amantadine Hydrochloride Capsule [Aidarex Pharmaceuticals Llc]
  • American Health Packaging
    Amantadine Hydrochloride Capsule [American Health Packaging]
  • Physicians Total Care, Inc.
    Amantadine Hydrochloride Capsule [Physicians Total Care, Inc.]
  • Aphena Pharma Solutions – Tennessee, Llc
    Amantadine Hydrochloride Capsule [Aphena Pharma Solutions – Tennessee, Llc]
  • Carilion Materials Management
    Amantadine Hydrochloride Capsule [Carilion Materials Management]

Login To Your Free Account